Surrozen Secures $95.1 Million Capital Infusion Following FDA Clearance for SZN-8141

Key numbers

Deal value	$95M
Share of market cap	27.6%

Key highlights

• Second closing milestone satisfied by FDA clearance of SZN-8141 IND application
• Approximately $95.1 million in expected gross proceeds before fees and expenses
• Funding supports clinical development of lead candidates SZN-8141 and SZN-8143
• First patient dosing in the Phase 1b/2a DUET clinical study scheduled for Q4 2026
• Initial clinical data from the DUET study anticipated in the second half of 2027

The Capital Raise Structure

Surrozen is set to receive approximately $95.1 million in gross proceeds, marking the second and final tranche of a two-part private placement originally established in March 2025. The funding was contingent upon the U.S. Food and Drug Administration clearing the company's Investigational New Drug application for SZN-8141. With the statutory 30-day review period now complete, the second closing is anticipated to occur on or about October 20, 2026. Following the transaction, the company is contractually obligated to file a new registration statement on Form S-3 within 30 days to facilitate the resale of common stock and associated warrants issued during this funding round.

Clinical Deployment and SZN-8141 Development

• Initiation of the DUET Phase 1b/2a study evaluating SZN-8141 in patients with diabetic macular edema
• Clinical expansion into neovascular age-related macular degeneration and other retinal vascular diseases
• Advancement of SZN-8143, a trifunctional antibody targeting inflammation and vascular leakage
• General corporate operations and working capital requirements through the H2 2027 data readout
• Registration of common stock and shares issuable upon exercise of pre-funded and Series E warrants

Strategic Rationale for the Wnt Pathway

The clearance of the SZN-8141 IND serves as a pivotal transition for Surrozen as it moves its Wnt-based ophthalmology pipeline into human clinical trials. SZN-8141 is designed as a bifunctional antibody that simultaneously acts as a Wnt agonist and a vascular endothelial growth factor antagonist. By targeting the Frizzled 4 receptor, the therapy aims to restore vascular integrity in the retina, potentially offering a differentiated alternative to existing anti-VEGF monotherapies. This dual-mechanism approach is intended to provide more durable anatomic control for patients suffering from sight-threatening conditions like diabetic macular edema, where current standards of care often face limitations in long-term efficacy.

Financial and Industry Context

Surrozen enters this clinical phase with a strengthened balance sheet, having reported $102.0 million in cash and cash equivalents as of June 30, 2026. The addition of $95.1 million in gross proceeds provides significant runway for the upcoming Phase 1b/2a trials. This capital raise aligns with broader 2026 trends in the biotechnology sector, where funding has become increasingly selective, favoring companies with de-risked assets and clear regulatory milestones. With a market capitalization of approximately $344.6 million and a 32.07% stock price increase over the past month, the company is leveraging improved market sentiment to fund its transition from a preclinical to a clinical-stage entity.

Down 21.6% since our story on 2 Oct: $30.00 when we broke it → $23.51 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$17.84
15 Sep	$17.77
16 Sep	$16.93
17 Sep	$16.94
18 Sep	$16.55
21 Sep	$16.53
22 Sep	$17.60
23 Sep	$16.16
24 Sep	$33.68
25 Sep	$29.54
28 Sep	$29.64
29 Sep	$31.98
30 Sep	$32.18
1 Oct	$30.00
2 Oct	$29.32
5 Oct	$29.13
6 Oct	$26.37
7 Oct	$25.14
8 Oct	$27.97
9 Oct	$29.69
12 Oct	$24.76
13 Oct	$23.51

Surrozen, Inc./DE · financial snapshot

Share price	$30.00
Market cap	$345M
Revenue (annual)	$3M
1-month price change	+32.07%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.